Design of Chitosan and Its Water Soluble Derivatives-Based Drug Carriers with Polyelectrolyte Complexes

Qing-Xi Wu 1,2, Dong-Qiang Lin 2,3 and Shan-Jing Yao 2,3,*

1 Integrated Biotechnology Laboratory, School of Life Science, Anhui University, Hefei 230601, China; E-Mail: wuqx@ahu.edu.cn
2 Key Laboratory of Biomass Chemical Engineering of Ministry of Education, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, China; E-Mail: lindq@zju.edu.cn
3 Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300072, China

* Author to whom correspondence should be addressed; E-Mail: yaosj@zju.edu.cn; Tel./Fax: +86-571-8795-1982.

External Editor: David Harding

Received: 9 October 2014; in revised form: 11 December 2014 / Accepted: 12 December 2014 / Published: 19 December 2014

Abstract: Chitosan, the cationic polysaccharide derived from the natural polysaccharide chitin, has been studied as a biomaterial for more than two decades. As a polycationic polymer with favorable properties, it has been widely used to form polyelectrolyte complexes with polyanions for various applications in drug delivery fields. In recent years, a growing number of studies have been focused on the preparation of polyelectrolyte complexes based on chitosan and its water soluble derivatives. They have been considered well-suited as biomaterials for a number of vital drug carriers with targeted/controlled release profiles, e.g., films, capsules, microcapsules. In this work, an overview highlights not only the favorable properties of chitosan and its water soluble derivatives but also the good performance of the polyelectrolyte complexes produced based on chitosan. Their various types of applications as drug carriers are reviewed in detail.

Keywords: chitosan; water soluble chitosan; drug carriers; polyelectrolyte complexes; targeted/controlled release
1. Introduction

With nonrenewable resources running out all over the world, more and more polysaccharides from the natural world have been explored as advanced functional biomaterials and new energy resources, especially in recent years. Among them, chitin is known as the second most abundant renewable polymer in nature next only to cellulose. Chitin extensively exists in the exoskeleton of crustaceans, e.g., crab shells, lobsters, shrimp. It can also be found in mollusk radulas, cephalopod beaks, insects, fungal cell walls. Chitosan is considered a cationic polysaccharide, which is obtained from chitin following an alkaline deacetylation. With remarkable structural and functional properties, chitosan and its water soluble derivatives have been concerned by researchers in fundamental science and industry application.

Chitosan is a linear copolymer composed by glucosamine and N-acetyl glucosamine units, via β-(1,4) linkages, namely 2-amino-2-deoxy-β-D-glucan (GlcN) (Figure 1a). It is the product of the deacetylation reaction of chitin (2-acetamido-2-deoxy-β-D-glucan (GlcNAc)). Chitosan is able to dissolve in acidic solutions, becoming a polycationic polymer with a high density of positive charges (–NH₃⁺ groups). It has favorable biological properties, such as no-toxicity, mucoadhesiveness, biocompatibility and, more importantly, the biodegradability, which means it could be digested by the bacteria in the human colon [1–3]. Recently, the water soluble derivatives of chitosan, hereafter water soluble chitosan (WSC), such as chitosan salts (Figure 1b), zwitterionic chitosan and chitosan oligomers, have drawn increasing attention due to their water-solubility [4–10]. WSC has the similar favorable properties with chitosan but can be dissolved in neutral aqueous media. Therefore, both of them are challenging biomaterials with potential vital applications in bioengineering and biopharmaceutical fields [11–14].

**Figure 1.** Structure of chitosan and chitosan salts.

![Structure of chitosan and chitosan salts](image)

As a macromolecule with positive charges, chitosan and WSC can chemically conjugate with a lot of anionic substrates forming polyelectrolyte complexes (PEC). These anionic substrates include both polyanionic polymers and small molecular substances, such as sodium alginate [15,16], hyaluronic acid [17], sodium cellulose sulfate (NaCS) [18], glutaraldehyde [19], genipin [20]. Based on chitosan and WSC, the materials normally used for the preparation of PEC to design new drug delivery carriers can be seen in Table 1.
Table 1. Materials normally used for the preparation of polyelectrolyte complexes (PEC) based on chitosan and water soluble chitosan (WSC).

| Polycationic Polyelectrolyte | Polyanionic Polyelectrolyte | Cross-Linking Agent | Preparation Method | Package Drugs | Reference |
|-----------------------------|-----------------------------|---------------------|--------------------|--------------|-----------|
| Chitosan                    | Sodium alginate             | Calcium chloride    | Coacervation        | Rifampicin   | [15]      |
| Chitosan                    | Hyaluronic acid             | TPP                 | Ionotropic gelation| Heparin      | [17]      |
| Chitosan                    | NaCS                        | —                   | Dipping-process    | 5-ASA        | [18]      |
| Chitosan                    | Carrageenan                 | Glutaraldehyde      | Complex coacervation| Pimentadoica oil | [19] |
| Chitosan                    | Carboxymethyl cellulose     | Genipin             | In situ synthesis  | —            | [20]      |
| Chitosan                    | Pectin                      | —                   | Wet granulation    | Theophylline | [21]      |
| Chitosan                    | Xanthan gum                 | —                   | Hot-melt extrusion | CPM          | [22]      |
| Chitosan                    | —                           | Polyethylene glycol | Emulsification    | 5-FU         | [23]      |
| WSCa                        | Poly-(L-aspartic acid)       | —                   | Coagulation        | BSA          | [9]       |
| WSCb                        | NaCS                        | PPS                 | Orifice-polymerization | Lactoferrin | [24]      |

TPP: pentasodium tripolyphosphate; NaCS: sodium cellulose sulfate; 5-ASA: 5-aminosalicylic acid; CPM: chlorpheniramine maleate; 5-FU: 5-fluorouracil; WSCa: chitosan with molecular weight 6 kDa and deacetylation degree 0.93; BSA: bovine serum albumin; WSCb: chitosan hydrochloride; PPS: Sodium polyphosphate.

The prepared PEC based on these substances exhibit favorable biological performances, such as a definite hydrophilic and swellable character, low interfacial tension and high permeability, favorable film-forming behavior, excellent biodegradability and good biocompatibility [25]. Based on these favorable performances, PECs have received the attention of more and more researchers for the preparation of drug carriers or tissue engineering scaffolds [26–29]. The details will be presented in the next sections of this review.

2. Properties of Chitosan and WSC

2.1. No-Toxicity

Chitosan is a well-known approved pharmaceutical excipient with no or low toxicity [30]. Chitosan has also been approved by the US Food and Drug Administration (FDA) for use in wound dressings [31] and is used as dietary additives in Japan, Italy and Finland [32]. Despite the lethal dose presented by chitosan as LD50 = 16 g/kg body weight when orally administered to mice, this level has been shown to be biodegradable [30,33]. In another study, Costa et al., showed that chitosan-based mouthwash possessed no genotoxicity and lower cytotoxicity than the commercial mouthwash [34]. Meanwhile, alcohol-free mouthwash based on water-soluble chitosan has also proved to have no cytotoxicity [35]. It had also
been confirmed that the toxicological side effects of chitosan are dependent on the molecular weight, degree of deacetylation and charge density of the molecule, specifically the toxicity is related to the molecular weight when at a high degree of deacetylation and it increases with increasing density [36].

2.2. Solubility

Chitosan is insoluble at neutral and high pH regions due to its molecular structure and $pK_a$ (6.2–7.0) [37,38]. It means that chitosan can be protonated at low pH in aqueous solutions [39]. Therefore, acidic solvents, such as diluted solutions of acetic acid (1%–3%, v/v) and citric acid (3%–4%, v/v) are usually needed to prepare chitosan solutions. However, the derivatives of chitosan, WSC can be directly dissolved in water under neutral pH conditions. It makes the process simpler while avoiding the use of acidic solvents; therefore WSC had received the attention of more and more researchers [37,40–44].

2.3. Biocompatibility

Chitosan has been widely used in the biomedical field, as it has already proved to be highly biocompatible [45,46]. Additionally, as a pharmaceutical excipient, WSCs like chitosan hydrochloride were approved by the European Pharmacopoeia (4th edition, 2002). Further, Marsiyana et al., verified that the chitosan-bound microtubes were highly biocompatible and the experimental cells were able to survive and proliferate at a similar rate as the control [47]. Besides, the chitosan derivative named zwitterionic chitosan (ZWC), which is soluble in water at pH’s below and above the $pI$, showed an excellent compatibility with the blood components and a good toleration upon an intraperitoneal (IP) injection [7]. Furthermore, the studies of Bajaj et al., confirmed that ZWC could be used as a new biocompatible pharmaceutical excipient and a functional biomaterial [8].

2.4. Mucoadhesiveness

Chitosan is a bioadhesive substance with vital applications due to its excellent mucoadhesive properties, when in a swollen state, based on its cationic character. The mucoadhesiveness of chitosan derives from non-covalent interactions between chitosan and mucin, such as electrostatic interactions and hydrogen bonds [48,49]. As a polycationic polymer with a high density of positive charges, it can adhere to both hard and soft tissues, such as epithelial and mucosal tissues, via hydration, hydrogen bonding and ionic interactions, and has been widely explored as drug carriers, especially for colon-specific delivery [50]. For instance, in the in vitro mucoadhesive tests, the prednisolone loaded alginate/chitosan microparticles prepared by the one-step method exhibited excellent mucoadhesiveness, whereas their other properties were not statistically significant different [51]. Recently, a new conception has been proposed for novel applications of chitosan. Fernandes et al., designed chitosan microspheres so as to serve as binders for Helicobacter pylori when facing a H. pylori gastric infection treatment [52], meaning that, after oral administration, the chitosan microspheres would remove H. pylori from infected patients, taking also the advantages of muco-bacterial adhesive properties.
2.5. Biodegradability

Chitosan is considered to be biodegradable in animal’s metabolism, as it can be degraded by enzymes which hydrolyze glycosidic bonds, like -GlcN-GlcN-, -GlcN-GlcNAc-, -GlcNAc-GlcN- and -GlcNAc-GlcNAc- linkages. It could also be hydrolyzed by certain human enzymes, especially lysozyme [53]. Besides, chitosan and its WSC-derivatives are promising biomaterials whose glycosidic bonds could be hydrolyzed in the human colon [3,54,55]. Based on the specific microflora of the colon-ecosystem, WSC-derivatives may be particularly hydrolyzed by β-glucosidase secreted by the colonic bacteria [56]. Additionally, it has already been confirmed that the biodegradability of chitosan in living organisms depends on the deacetylation degree and on its molecular weight [57–59].

3. Performances of PEC Based on Chitosan and WSC

PECs are polymeric materials chemically formed by polyelectrolytes of opposite charges. They can be fabricated with polycationic and polyanionic macromolecules or polyelectrolytes and surfactants with opposite charges [60]. Based on the favorable properties of chitosan/WSC, the PECs formed by chitosan/WSC and anionic substrates (such as sodium alginate, hyaluronic acid, pentasodium tripolyphosphate) may present many excellent performances, as following: (1) Good hydrophilic and swellable character; (2) Low interfacial tension and high permeability; (3) Excellent biodegradability; (4) Good biocompatibility; (5) Favorable film-forming behavior.

The good hydrophilic and swellable characters of PECs are due to their ability to swell in water and biological fluids, and retain a significant fraction of water within their latticed structures [61,62]. Their low interfacial tension and higher permeability make PECs well-suited biomaterials for the preparation of targeted/controlled drug release carriers. Due to an excellent biodegradability in the colon and good biocompatibility with organisms, PECs could be good candidates for designing new oral colon-specific drug delivery systems (OCDDS). More importantly, because of their favorable film-forming behavior, the drug carriers prepared with PECs might be the base for various formulations, such as films, capsules, microcapsules, microparticles or nanoparticles.

4. Drug Carriers Designed with PECs Based on Chitosan and WSC

4.1. Films

PECs, based on chitosan and WSC, might be used as the controlled release drug carriers for designing new skin drug delivery systems [63]. As can be seen in Table 2, some cross-linking agents, like glycerol and PEG200, were used to improve the performances of PEC films which were most of the times prepared via casting but also by self-assembly methods using some proper templates [63–66].
Table 2. Drug carriers prepared with films of polyelectrolyte complexes (PECs).

| Polycationic Polyelectrolyte | Polyanionic Polyelectrolyte | Cross-Linking Agent | Preparation Method | Package Drugs | Reference |
|-----------------------------|-----------------------------|---------------------|-------------------|---------------|-----------|
| Chitosan                    | Polyacrylic acid            | Glycerol/PEG200/     | Cast              | Paracetamol   | [63]      |
|                             |                             | Hydrovance/Trehalose |                   | 5-ASA        |           |
| Chitosan                    | NaCS                        | —                   | Cast              | Salicylic acid/Phenol | [65] |
| Chitosan                    | Polyalkyleneoxide-maleic acid copolymer | —                   | Cast              |               | [66] |
| Chitosan                    | Hyaluronic acid             | —                   | Self-assembly     |               |           |

In a previous study, Zhu et al., confirmed that the PEC films based on chitosan (molecular weight of 135.3 kDa) and NaCS (molecular weight of 710.8 kDa) showed the highest susceptibility to the hydrolysis by pepsin, amylase and trypsin. In addition, the disintegration time of the PEC films along the gastrointestinal tract (GIT) was different depending on the PEC formulations (Figure 2) [59]. The mass ratios of chitosan to NaCS had great influence on the morphology of the formulations and had important effects on the swelling properties and permeability of the films (Figure 3). A study on the release of paracetamol-loaded PEC films showed that the permeability of the films was closely related to the swelling properties and significantly influenced by the mass ratios, molecular weights and pH values [64]. These results indicated that the PEC films could be used as good candidates for the GIT delivery systems, especially for designing new colon-specific drug delivery systems.

Figure 2. In vitro degradation profiles of chitosan/NaCS films in simulated gastric fluid (SGF, stage I), simulated intestinal fluid (SIF, stage II) and simulated colonic fluid (SCF, stage III). Sample 1: 563.3 kDa chitosan and 169.7 kDa NaCS; sample 2: 563.3 kDa chitosan and 31.2 kDa NaCS; sample 3: 135.3 kDa chitosan and 710.8 kDa NaCS; sample 4: 563.3 kDa chitosan and 710.8 kDa NaCS. Modified and cited from Zhu et al. [59].
Figure 3. SEM morphology of chitosan/NaCS films prepared with different mass ratios. Mass ratios of chitosan to NaCS of (a) 1:4; (b) 1:2; (c) 3:4 and (d) 1:1. Chitosan with molecular weight 563.3 kDa and NaCS with molecular weight 710.8 kDa were used. Modified and cited from Zhu et al. [64].

4.2. Hard Hollow Capsules

Hard hollow capsules made up of chitosan have been a research concern since the 1990s [55]. Due to the solubility of chitosan in acidic conditions, hard hollow capsules prepared with chitosan must be coated with enteric coatings, like hydroxypropyl methylcellulose phthalate (HPMCP), to prevent disintegration during their passage through the stomach and small intestine [67]. These kinds of chitosan capsules proved to be useful carriers for colon-specific delivery of drugs like n-dodecyl-β-D-maltopyranoside and rebamipide, and could increase the effects of drugs by enhancing their absorption by the intestinal membranes [68,69].

However, hard hollow capsules prepared with PEC and based on chitosan were seldom reported. In the past few years, Wang et al., developed a novel PEC capsule system which was formed by chitosan and sodium cellulose sulfate (NaCS) [18]. The PEC-based hard hollow capsules had a relatively homogeneous and smooth morphology (Figure 4a). In vitro degradation studies showed that the PEC films could be degraded by colon microflora and hydrolyzed in simulated gastrointestinal fluids, like simulated gastric (SGF) and intestinal fluids (SIF) (Figure 4b–f). More importantly, this kind of PEC-based hard hollow capsules loaded with 5-ASA may release about 80% of the drug in the simulated colonic fluid (SCF) during 4 h, indicating an excellent microflora-activated and colon-specific performance (Figure 4g). All these results indicated that the PEC-based capsules could be good candidates for designing new colon-specific drug delivery systems [18,70].
**Figure 4.** SEM morphology of the capsules and films, and the *in vitro* drug release profiles based on NaCS-chitosan. (a) Hard hollow capsules; (b) Films at 0 h in the *in vitro* experiment; (c) Films at 1 h in the *in vitro* experiment (SGF); (d) Films at 5 h in the *in vitro* experiment (SIF); (e) Films at 11 h in the *in vitro* experiment (SCF); (f) Films at 17 h in the *in vitro* experiment (SCF); (g) *In vitro* drug release profiles of 5-ASA from drug-loaded capsules based on NaCS-chitosan films or not. Stage I, in the SGF for 1 h; stage II, in the SIF for 4 h; stage III, in the SCF for 7 h. Sample C1(■), sample C2(●), sample C3 (▲), sample C1 in PBS after 5 h (□), sample C2 in PBS after 5 h (○), sample C3 in PBS after 5 h (△), capsule without NaCS-chitosan (◊). Samples (C1, C2, C3) were prepared with NaCS-chitosan films, gelatin and carrageenan as raw materials; capsules without NaCS-chitosan were prepared with gelatin and carrageenan as raw materials by the same method. Modified and cited from Wang et al. [18].

4.3. Microcapsules

Microcapsules of PEC based on chitosan and WSC, have gained large attention due to their potential applications (Table 3). With a large surface area, PEC microcapsules were designed in order to carry various drugs for targeted/controlled release [71–76]. Besides, they have also been widely studied in several biotechnological fields, such as fermentation with immobilized cells [77] and as vehicles for delivering probiotic bacteria [78,79].
Table 3. Drug carriers prepared with polyelectrolyte complexes (PEC) microcapsules.

| Polycationic Polyelectrolyte | Polyanionic Polyelectrolyte | Cross-Linking Agent | Preparation Method | Package Drugs | Reference |
|------------------------------|------------------------------|---------------------|--------------------|---------------|-----------|
| Chitosan                     | NaCS                         | Sodium polyphosphate| Orifice-polymerization| 5-ASA | [71]      |
| Chitosan                     | Sodium alginate              | —                   | Electro spray      | Albumin | [72]      |
| Chitosan                     | Sodium alginate              | Calcium chloride    | Modified orifice   | Albendazole| [73]      |
| Chitosan                     | NaCS                         | —                   | Self-assembly      | —      | [74]      |
| Chitosan kappa-carrageenan   | Sodium alginate              | Glutaraldehyde/Genipin/Tannic acid | Emulsion | Neem Seed Oil | [75] |
| WSCb                         | NaCS                         | Sodium polyphosphate| Orifice-polymerization| Lactoferrin | [76]     |

Figure 5. SEM morphology of the microcapsules and pure 5-ASA, and the in vitro drug release profiles. (a) Transection image of the double-walled capsule; (b) Transection image of the outer coated membrane layer (outer wall) and the loaded drug of 5-ASA; (c) Pure 5-ASA; (d) In vitro drug release studies in SCF (pH 6.4) and PBS (pH 6.4); (e) Nonlinear curve fitting of accumulative drug release in SCF (pH 6.4). Microcapsules were prepared with NaCS, WSC, and PPS as raw materials. Modified and cited from Wu et al. [71].

Recently, novel PEC microcapsules based on NaCS, chitosan/WSC and sodium polyphosphate (PPS) were developed following simple processes, and this type of microcapsules could be used for designing new colon-specific drug delivery systems [24,71,76]. In this system, NaCS is the polyanion with $–SO_3^−$ groups while chitosan/WSC is the polycation with $–NH_3^+$ groups, PPS was used as a cross-linking agent. Based on the PEC obtained by ionization, spherical microcapsules were prepared by the
orifice-polymerization method. These materials had been successfully used to encapsulate two kinds of model drugs: 5-aminosalicylic acid (5-ASA, a small molecular drug) [71] and lactoferrin (LF, a protein drug) [24,76].

It was verified that the PEC microcapsules loaded with 5-ASA had a relatively high loading efficiency (60.77%) and encapsulation efficiency (90.03%). SEM micrographs showed that the microcapsules were involved by a double-walled structure (shell) (Figure 5a,b). SEM transection images showed that 5-ASA entrapped in the microcapsule was in a crystal form (Figure 5b,c). In vitro release analysis showed that the drug was completely released in the simulated colonic fluid (SCF, pH 6.4), and the drug release was under the mechanism of anomalous transport (Figure 5d,e) [71].

The microcapsules made of PEC and loaded with LF were also successfully prepared by Wu et al. [24,76]. SEM studies showed that the PEC microcapsules had a typical wall-capsule structure with smooth surfaces (Figure 6a,b). Fourier transform infrared spectroscopy (FT-IR) spectra analysis indicated that –NH₃⁺ of chitosan/WSC, –SO₃⁻ of NaCS and –[P₂O₅₄⁻]⁻ of PPS may react to form PEC. A schematic illustration of polyelectrolyte complexes formation process can be seen in Figure 6c. Drug loading and encapsulation efficiency studies also showed that the PEC microcapsules had a relatively high loading efficiency (49.06%) and encapsulation efficiency (86.3%). In vitro release studies showed that the microcapsules had a regular drug release behavior and the drug was released sustainably and completely in SCF (pH 5.5–7.0) [24].

**Figure 6.** SEM morphology of the LF loaded NaCS-WSC-PPS microcapsules, and its formation process. (a) External appearance; (b) Transection image; (c) Schematic illustration of polyelectrolyte complexes formation process. Modified and cited from Wu et al. [24].
Table 4. Drug carriers prepared with microparticles or nanoparticles of polyelectrolyte complexes (PEC).

| Polycationic Polyelectrolyte | Polyanionic Polyelectrolyte | Cross-Linking Agent | Preparation Method          | Package Drugs          | Reference |
|------------------------------|-----------------------------|---------------------|-----------------------------|------------------------|-----------|
| Chitosan                     | Dextran sulfate             | —                   | Self-assembly               | Insulin                | [80]      |
| WSCc                         | Sodium alginate             | Calcium chloride    | Coaxial air-flow           | Naproxen               | [10]      |
| Chitosan                     | Pectin                      | Tripolyphosphate    | Emulsion                   | Gliclazide             | [81]      |
| Chitosan                     | Hyaluronan sodium salt      | —                   | Stirring (Non-solvent)      | Chloramphenicol succinate sodium salt/ Cefotaxime sodium salt | [82]      |
| Chitosan                     | Polybetaine                 | —                   | Stirring                   | Chloramphenicol succinate sodium salt | [83]      |
| Chitosan                     | Hyaluronic acid             | —                   | Self-assembly              | Paclitaxel             | [84]      |
| Chitosan                     | Carboxymethyl gum kondagogu | —                   | Coacervation               | Ofloxacin              | [85]      |
| Chitosan                     | Sodium alginate             | —                   | Ionic gelation             | Amoxicilllin           | [86]      |

WSCc: oligochitosan with deacetylation degree >85% and molecular weight around 3 kDa.
4.4. Microparticles/Nanoparticles

Microparticles or nanoparticles of PEC based on chitosan and WSC are also popular forms of drug carriers, as can be seen in Table 4. These are the most common strategies to improve the bioavailability of protein drugs via micro- and nanoencapsulation techniques. For example, in order to improve insulin bioavailability, Balabushevich et al., developed a kind of multifunctional protein-polymer microparticles via self-assembly method [80]. When using this multicomponent of insulin loaded microparticle system, the oral bioavailability of loaded-insulin improved due to the cumulative effect of each component, and the blood glucose level effectively lowered in the diabetic rats.

Besides, chitosan was usually used to coat hyaluronic acid-paclitaxel nanoparticles to prepare pH-responsive PEC drug-loaded-nanoparticles [84,87]. It is well-known that paclitaxel is a mitotic inhibitor used in cancer chemotherapy [88,89]. This kind of PEC nanoparticles takes several favorable advantages, such as a simple and feasible process, with a targeting and pH-sensitive release. For instance, the formulation of ofloxacin loaded nanoparticles provided a sustained drug release with 27% of the drug getting released in 12 h in the \textit{in vitro} tests [90]. Guo et al., designed a kind of novel polyelectrolyte complex nanoparticles (PCNs) which are capable of associating bovine serum albumin (BSA), and \textit{in vitro} studies showed that the system could keep a sustained drug release manner for 1 month without burst release [91]. Anitha et al., developed a combinatorial nanomedicine of 5-FU and curcumin (CUR) loaded nanoparticles, \textit{in vitro} drug release profile showed a sustained release over a period of 4 days, further \textit{in vivo} experiments in mouse verified an improved plasma concentration which could be prolonged up to 72 h [92]. Therefore, microparticles or nanoparticles of PEC based on chitosan and WSC could potentially be used in vital applications, such as designing of targeted/controlled drug delivery systems.

5. Conclusions

In view of the vital properties, such as no-toxicity, high biocompatibility and excellent biodegradability, chitosan and its water soluble derivatives (WSC) will be challenging biomaterials with potential applications in pharmaceutical fields, especially in the targeted/controlled release drug delivery field. Further, based on the favorable performances, such as good hydrophilic and swellable character, low interfacial tension and high permeability and favorable film-forming behavior, chitosan-based polyelectrolyte complexes, in proper forms like films, capsules and microparticles, might become important drug carriers with a promising application prospect.

Acknowledgments

This work was supported by the Doctoral Research Start-up Fund of Anhui University, the National Natural Science Foundation of China and the Doctoral Programs Foundation of Ministry of Education of China.

Conflicts of Interest

The authors declare no conflict of interest.
References

1. Onishi, H.; Machida, Y. Biodegradation and distribution of water-soluble chitosan in mice. Biomaterials 1999, 20, 175–182.
2. Xia, W.S.; Liu, P.; Liu, J. Advance in chitosan hydrolysis by non-specific cellulases. Bioresour. Technol. 2008, 99, 6751–6762.
3. Zhang, H.; Alsarra, I.A.; Neau, S.H. An in vitro evaluation of a chitosan-containing multiparticulate system for macromolecule delivery to the colon. Int. J. Pharm. 2002, 239, 197–205.
4. Zhang, Y.Q.; Niu, Y.G.; Luo, Y.C.; Ge, M.; Yang, T.; Yu, L.L.; Wang, Q. Fabrication, characterization and antimicrobial activities of thymol-loaded zein nanoparticles stabilized by sodium caseinate-chitosan hydrochloride double layers. Food Chem. 2014, 142, 269–275.
5. Dang, Q.F.; Yan, J.Q.; Li, Y.; Cheng, X.J.; Liu, C.S.; Chen, X.G. Chitosan acetate as an active coating material and its effects on the storing of Prunus avium L. J. Food Sci. 2010, 75, S125–S131.
6. Parodi, B.; Russo, E.; Caviglioli, G.; Baldassari, S.; Gaglianone, N.; Schito, A.M.; Cafaggi, S. A chitosan lactate/poloxamer 407-based matrix containing Eudragit RS microparticles for vaginal delivery of econazole: Design and in vitro evaluation. Drug Dev. Ind. Pharm. 2013, 39, 1911–1920.
7. Xu, P.S.; Bajaj, G.; Shugg, T.; van Alstine, W.G.; Yeo, Y. Zwitterionic chitosan derivatives for pH-sensitive stealth coating. Biomacromolecules 2010, 11, 2352–2358.
8. Bajaj, G.; van Alstine, W.G.; Yeo, Y. Zwitterionic chitosan derivative, a new biocompatible pharmaceutical excipient, prevents endotoxin-mediated cytokine release. PLoS One 2012, 7, 1–10.
9. Shu, S.J.; Zhang, X.G.; Teng, D.Y.; Wang, Z.; Li, C.X. Polyelectrolyte nanoparticles based on water-soluble chitosan-poly(l-aspartic acid)-polyethylene glycol for controlled protein release. Carbohyd. Res. 2009, 344, 1197–1204.
10. Čalija, B.; Cekić, N.; Savić, S.; Daniels, R.; Marković, B.; Milić, J. pH-sensitive microparticles for oral drug delivery based on alginate/oligochitosan/Eudragit® L100–55 “sandwich” polyelectrolyte complex. Colloid. Surf. B 2013, 110, 395–402.
11. Franco, R.A.; Nguyen, T.H.; Lee, B.T. Preparation and characterization of electrospun PCL/PLGA membranes and chitosan/gelatin hydrogels for skin bioengineering applications. J. Mater. Sci. Mater. M. 2011, 22, 2207–2218.
12. Mahmoudzadeh, M.; Fassihi, A.; Emami, J.; Davies, N.M.; Dorkoosh, F. Physicochemical, pharmaceutical and biological approaches toward designing optimized and efficient hydrophobically modified chitosan-based polymeric micelles as a nanocarrier system for targeted delivery of anticancer drugs. J. Drug Target. 2013, 21, 693–709.
13. Supper, S.; Anton, N.; Seidel, N.; Riemenschneider, M.; Curdy, C.; Vandamme, T. Thermosensitive chitosan/glycerophosphate-based hydrogel and its derivatives in pharmaceutical and biomedical applications. Expert Opin. Drug Deliv. 2014, 11, 249–267.
14. Zakhem, E.; Raghavan, S.; Bitar, K.N. Neo-innervation of a bioengineered intestinal smooth muscle construct around chitosan scaffold. Biomaterials 2014, 35, 1882–1889.
15. Lacerda, L.; Parize, A.L.; Fávere, V.; Laranjeira, M.C.M.; Stulzer, H.K. Development and evaluation of pH-sensitive sodium alginate/chitosan microparticles containing the antituberculosis drug rifampicin. Mat. Sci. Eng. C 2014, 39, 161–167.
16. Xiong, Y.; Yan, K.; Bentley, W.E.; Deng, H.B.; Du, Y.M.; Payne, G.F.; Shi, X.W. Compartmentalized Multilayer Hydrogel Formation Using a Stimulus-Responsive Self-Assembling Polysaccharide. *ACS Appl. Mater. Inter.* **2014, 6**, 2948–2957.

17. Oyarzun-Ampuero, F.A.; Brea, J.; Loza, M.I.; Torres, D.; Alonso, M.J. Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma. *Int. J. Pharm.* **2009, 381**, 122–129.

18. Wang, M.J.; Xie, Y.L.; Zheng, Q.D.; Yao, S.J. A novel, potential microflora-activated carrier for a colon-specific drug delivery system and its characteristics. *Ind. Eng. Chem. Res.* **2009, 48**, 5276–5284.

19. Dima, C.; Cotarlet, M.; Alexe, P.; Dima, S. Microencapsulation of essential oil of pimento [*Pimenta dioica* (L) Merr.] by chitosan/k-carrageenan complex coacervation method. *Innov. Food Sci. Emerg.* **2014, 22**, 203–211.

20. Kaihara, S.; Suzuki, Y.; Fujimoto, K. *In situ* synthesis of polysaccharide nanoparticles via polyanion complex of carboxymethyl cellulose and chitosan. *Colloid. Surf. B.* **2011, 85**, 343–348.

21. Pandey, S.; Mishra, A.; Raval, P.; Patel, H.; Gupta, A.; Shah, D. Chitosan-pectin polyelectrolyte complex as a carrier for colon targeted drug delivery. *J. Young Pharm.* **2013, 5**, 160–166.

22. Fukuda, M.; Peppas, N.A.; McGinity, J.W. Properties of sustained release hot-melt extruded tablets containing chitosan and xanthan gum. *Int. J. Pharm.* **2006, 310**, 90–100.

23. Ganguly, K.; Aminabhavi, T.M.; Kulkarni, A.R. Colon targeting of 5-fluorouracil using polyethylene glycol cross-linked chitosan microspheres enteric coated with cellulose acetate phthalate. *Ind. Eng. Chem. Res.* **2011, 50**, 11797–11807.

24. Wu, Q.X.; Zhang, Q.L.; Lin, D.Q.; Yao, S.J. Characterization of novel lactoferrin loaded capsules prepared with polyelectrolyte complexes. *Int. J. Pharm.* **2013, 455**, 124–131.

25. Hamman, J.H. Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems. *Mar. Drugs* **2010, 8**, 1305–1322.

26. Luo, Y.C.; Wang, Q. Recent development of chitosan-based polyelectrolyte complexes with natural polysaccharides for drug delivery. *Int. J. Biol. Macromol.* **2014, 64**, 353–367.

27. Yan, S.F.; Zhang, K.X.; Liu, Z.W.; Zhang, X.; Gan, L.; Cao, B.; Chen, X.S.; Cui, L.; Yin, J.B. Fabrication of poly(L-glutamic acid)/chitosan polyelectrolyte complex porous scaffolds for tissue engineering. *J. Mater. Chem. B* **2013, 1**, 1541–1551.

28. Ma, G.P.; Wang, Z.L.; Chen, J.; Yin, R.X.; Chen, B.L.; Nie, J. Freeze-dried chitosan-sodium hyaluronate polyelectrolyte complex fibers as tissue engineering scaffolds. *New J. Chem.* **2014, 38**, 1211–1217.

29. Busilacchi, A.; Gigante, A.; Mattioli-Belmonte, M.; Manzotti, S.; Muzzarelli, R. Chitosan stabilizes platelet growth factors and modulates stem cell differentiation toward tissue regeneration. *Carbohydr. Polym.* **2013, 98**, 665–676.

30. Arai, K.; Kinumaki, T.; Fujita, T. Toxicity of chitosan. *Bull. Tokai Region. Fish. Res. Lab.* **1968, 56**, 88–94.

31. Wedmore, I.; McManus, J.G.; Pusateri, A.E.; Holcomb, J.B. A special report on the chitosan-based hemostatic dressing: Experience in current combat operations. *J. Trauma* **2006, 60**, 655–658.

32. Illum, L. Chitosan and its use as a pharmaceutical excipient. *Pharm. Res.* **1998, 15**, 1326–1331.

33. Singh, V.; Tiwari, M. Hydrophobic modification of chitosan and its physicochemical evaluation as sustained release tablet formulation. *Asian J. Chem.* **2011, 23**, 2141–2150.
34. Costa, E.M.; Silva, S.; Costa, M.R.; Pereira, M.; Campos, D.A.; Odila, J.; Madureira, A.R.; Cardelle-Cobas, A.; Tavaria, F.K.; Rodrigues, A.S.; et al. Chitosan mouthwash: Toxicity and in vivo validation. Carbohydr. Polym. 2014, 111, 385–392.

35. Chen, C.Y.; Chung, Y.C. Antibacterial effect of water-soluble chitosan on representative dental pathogens Streptococcus Mutans and Lactobacilli Brevis. J. Appl. Oral Sci. 2012, 20, 620–627.

36. Kean, T.; Thanou, M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Deliver. Rev. 2010, 62, 3–11.

37. Hawary, D.L.; Motaleb, M.A.; Farag, H.; Guirguis, O.W.; Elsabee, M.Z. Water-soluble derivatives of chitosan as a target delivery system of Tc-99m to some organs in vivo for nuclear imaging and biodistribution. J. Radioanal. Nucl. Chem. 2011, 290, 557–567.

38. Hejazi, R.; Amiji, M. Chitosan-based gastrointestinal delivery systems. J. Control. Release 2003, 89, 151–165.

39. Nunthanid, J.; Huanbutta, K.; Luangtana-anan, M.; Sriamornsak, P.; Limmatvapirat, S.; Puttipipatkhachorn, S. Development of time-, pH-, and enzyme-controlled colonic drug delivery using spray-dried chitosan acetate and hydroxypropyl methylcellulose. Eur. J. Pharm. Biopharm. 2008, 68, 253–259.

40. Shu, X.Z.; Zhu, K.J. Controlled drug release properties of ionically cross-linked chitosan beads: The influence of anion structure. Int. J. Pharm. 2002, 233, 217–225.

41. Rai, G.; Jain, S.K.; Agrawal, S.; Bhadra, S.; Pancholi, S.S.; Agrawal, G.P. Chitosan hydrochloride based microspheres of albendazole for colonic drug delivery. Pharmazie 2005, 60, 131–134.

42. Sobol, M.; Bartkowiak, A.; de Haan, B.; de Vos, P. Cytotoxicity study of novel water-soluble chitosan derivatives applied as membrane material of alginate microcapsules. J. Biomed. Mater. Res. A 2013, 101, 1907–1914.

43. Xiao, C.M.; Sun, F. Fabrication of distilled water-soluble chitosan/alginate functional multilayer composite microspheres. Carbohydr. Polym. 2013, 98, 1366–1370.

44. Sheng, Y.; He, H.J.; Zou, H. Poly(lactic acid) nanoparticles coated with combined WGA and water-soluble chitosan for mucosal delivery of beta-galactosidase. Drug Deliv. 2014, 21, 370–378.

45. Keong, L.C.; Halim, A.S. In vitro models in biocompatibility assessment for biomedical-grade chitosan derivatives in wound management. Int. J. Mol. Sci. 2009, 10, 1300–1313.

46. Muzzarelli, R.; Baldassarre, V.; Conti, F.; Ferrara, P.; Biagini, G.; Gazzanelli, G.; Vasi, V. Biological activity of chitosan: Ultrastructural study. Biomaterials 1988, 9, 247–252.

47. Henricus, M.M.; Fath, K.R.; Menzenski, M.Z.; Banerjee, I.A. Morphology controlled growth of chitosan-bound microtubes and a study of their biocompatibility and antibacterial activity. Macromol. Biosci. 2009, 9, 317–325.

48. Bravo-Osuna, I.; Vauthier, C.; Farabollini, A.; Palmieri, G.F.; Ponchel, G. Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials 2007, 28, 2233–2243.

49. Meng-Lund, E.; Muff-Westergaard, C.; Sander, C.; Madelung, P.; Jacobsen, J. A mechanistic based approach for enhancing buccal mucoadhesion of chitosan. Int. J. Pharm. 2014, 461, 280–285.

50. Gulbake, A.; Jain, S.K. Chitosan: A potential polymer for colon-specific drug delivery system. Expert Opin. Drug Deliv. 2012, 9, 713–729.
51. Wittaya-areekul, S.; Kruenate, J.; Prahsarn, C. Preparation and in vitro evaluation of mucoadhesive properties of alginate/chitosan microparticles containing prednisolone. *Int. J. Pharm.* 2006, 312, 113–118.

52. Fernandes, M.; Gonçalves, I.C.; Nardecchia, S.; Amaral, I.F.; Barbosa, M.A.; Martins, M.C.L. Modulation of stability and mucoadhesive properties of chitosan microspheres for therapeutic gastric application. *Int. J. Pharm.* 2013, 454, 116–124.

53. Muzzarelli, R. Human enzymatic activities related to the therapeutic administration of chitin derivatives. *Cell. Mol. Life Sci.* 1997, 53, 131–140.

54. Sinha, V.R.; Kumria, R. Polysaccharides in colon-specific drug delivery. *Int. J. Pharm.* 2001, 224, 19–38.

55. Tozaki, H.; Komoiike, J.; Tada, C.; Maruyama, T.; Terabe, A.; Suzuki, T.; Yamamoto, A.; Muranishi, S. Chitosan capsules for colon-specific drug delivery: Improvement of insulin absorption from the rat colon. *J. Pharm. Sci.* 1997, 86, 1016–1021.

56. Orienti, I.; Cerchiara, T.; Luppi, B.; Bigucci, F.; Zuccari, G.; Zecchi, V. Influence of different chitosan salts on the release of sodium diclofenac in colon-specific delivery. *Int. J. Pharm.* 2002, 238, 51–59.

57. Yang, Y.M.; Hu, W.; Wang, X.D.; Gu, X.S. The controlling biodegradation of chitosan fibers by N-acetylation in vitro and in vivo. *J. Mater. Sci.-Mater. M.* 2007, 18, 2117–2121.

58. Xu, J.; McCarthy, S.P.; Gross, R.A.; Kaplan, D.L. Chitosan film acylation and effects on biodegradability. *Macromolecules* 1996, 29, 3436–3440.

59. Zhu, L.Y.; Lin, D.Q.; Yao, S.J. Biodegradation of polyelectrolyte complex films composed of chitosan and sodium cellulose sulfate as the controllable release carrier. *Carbohyd. Polym.* 2010, 82, 323–328.

60. Thunemann, A.F.; Muller, M.; Dautzenberg, H.; Joanny, J.; Lowen, H. Polyelectrolytes with defined molecular architecture II polyelectrolyte complexes. *Adv. Polym. Sci.* 2004, 166, 113–171.

61. Ramaraj, B.; Radhakrishnan, G. Hydrogel capsules for sustained drug-release. *J. Appl. Polym. Sci.* 1994, 51, 979–988.

62. II’INA, A.V.; Varlamov, V.P. Chitosan-based polyelectrolyte complexes: A review. *Appl. Biochem. Microbiol.* 2005, 41, 5–11.

63. Silva, C.L.; Pereira, J.C.; Ramalho, A.; Pais, A.A.C.C.; Sousa, J.J.S. Films based on chitosan polyelectrolyte complexes for skin drug delivery: Development and characterization. *J. Membrane Sci.* 2008, 320, 268–279.

64. Zhu, L.Y.; Yan, X.Q.; Zhang, H.M.; Lin, D.Q.; Yao, S.J.; Jiang, L. Determination of apparent drug permeability coefficients through chitosan-sodium cellulose sulfate polyelectrolyte complex films. *Acta Phys.-Chim. Sin.* 2014, 30, 365–370.

65. Yoshizawa, T.; Shin-ya, Y.; Hong, K.; Kajiuchi, T. pH- and temperature-sensitive release behaviors from polyelectrolyte complex films composed of chitosan and PAOMA copolymer. *Eur. J. Pharm. Biopharm.* 2005, 59, 307–313.

66. Feng, Q.; Zeng, G.; Yang, P.; Wang, C.; Cai, J. Self-assembly and characterization of polyelectrolyte complex films of hyaluronic acid/chitosan. *Colloid. Surf. A* 2005, 257–258, 85–88.
67. Tozaki, H.; Odoriba, T.; Okada, N.; Fujita, T.; Terabe, A.; Suzuki, T.; Okabe, S.; Muranishi, S.; Yamamoto, A. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. *J. Control. Release* **2002**, *82*, 51–61.

68. Fetih, G.; Lindberg, S.; Itoh, K.; Okada, N.; Fujita, T.; Habib, F.; Artersson, P.; Attia, M.; Yamamoto, A. Improvement of absorption enhancing effects of *n*-dodecyl-β-D-maltopyranoside by its colon-specific delivery using chitosan capsules. *Int. J. Pharm.* **2005**, *293*, 127–135.

69. Huang, B.B.; Li, G.F.; Luo, J.H.; Duan, L.; Nobuaki, K.; Akira, Y. Permeabilities of rebamipide via rat intestinal membranes and its colon specific delivery using chitosan capsule as a carrier. *World J. Gastroenterol.* **2008**, *14*, 4928–4937.

70. Wang, M.J.; Xie, Y.L.; Chen, Z.J.; Yao, S.J. Optimizing preparation of NaCS-chitosan complex to form a potential material for the colon-specific drug delivery system. *J. Appl. Polym. Sci.* **2010**, *117*, 3001–3012.

71. Wu, Q.X.; Yao, S.J. Novel NaCS-CS-PPS microcapsules as a potential enzyme-triggered release carrier for highly-loading 5-ASA. *Colloid. Surf. B* **2013**, *109*, 147–153.

72. Fukui, Y.; Maruyama, T.; Iwamatsu, Y.; Fujii, A.; Tanaka, T.; Ohmukai, Y.; Matsuyama, H. Preparation of monodispersed polyelectrolyte microcapsules with high encapsulation efficiency by an electrospay technique. *Colloid. Surf. A* **2010**, *370*, 28–34.

73. Simi, S.P.; Saraswathi, R.; Sankar, C.; Krishnan, P.N.; Dilip, C.; Ameena, K. Formulation and evaluation of Albendazole microcapsules for colon delivery using chitosan. *Asian Pac. J. Trop. Med.* **2010**, *3*, 374–378.

74. Xie, Y.L.; Wang, M.J.; Yao, S.J. Preparation and characterization of biocompatible microcapsules of sodium cellulose sulfate/chitosan by means of layer-by-layer self-assembly. *Langmuir* **2009**, *25*, 8999–9005.

75. Devi, N.; Maji, T.K. Effect of crosslinking agent on Neem (*Azadirachta Indica A. Juss.*) Seed Oil (NSO) encapsulated microcapsules kappa-carrageenan and chitosan polyelectrolyte complex. *J. Macromol. Sci. A* **2009**, *46*, 1114–1121.

76. Wu, Q.X.; Li, M.Z.; Yao, S.J. Performances of NaCS-WSC protein drug microcapsules with different degree of substitution of NaCS using sodium polyphosphate as cross-linking agent. *Cellulose* **2014**, *21*, 1897–1908.

77. Yu, W.T.; Song, H.Y.; Zheng, G.S.; Liu, X.D.; Zhang, Y.; Ma, X.J. Study on membrane characteristics of alginate-chitosan microcapsule with cell growth. *J. Membr. Sci.* **2011**, *377*, 214–220.

78. Cook, M.T.; Tzortzis, G.; Charalampopoulos, D.; Khutoryanskiy, V.V. Production and evaluation of dry alginate-chitosan microcapsules as an enteric delivery vehicle for probiotic bacteria. *Biomacromolecules* **2011**, *12*, 2834–2840.

79. Argin, S.; Kofinas, P.; Lo, Y.M. The cell release kinetics and the swelling behavior of physically crosslinked xanthan-chitosan hydrogels in simulated gastrointestinal conditions. *Food Hydrocolloid.* **2014**, *40*, 138–144.

80. Balabushevich, N.G.; Pechenkin, M.A.; Shibanova, E.D.; Volodkin, D.V.; Mikhchalchik, E.V. Multifunctional polyelectrolyte microparticles for oral insulin delivery. *Macromol. Biosci.* **2013**, *13*, 1379–1388.
81. Barakat, N.S.; Almurshedi, A.S. Preparation and characterization of chitosan microparticles for oral sustained delivery of Gliclazide: In Vitro/In Vivo evaluation. Drug Dev. Res. 2011, 72, 235–246.
82. Vasiliu, S.; Popa, M.; Luca, C. Evaluation of retention and release processes of two antibiotics from the biocompatible core-shell microparticles. Eur. Polym. J. 2008, 44, 3894–3898.
83. Racovita, S.; Vasiliu, S.; Vlad, C.D. New drugs delivery systems based on polyelectrolyte complexes. Rev. Roum. Chim. 2010, 55, 659–666.
84. Li, J.; Huang, P.; Chang, L.; Long, X.; Dong, A.; Liu, J.; Chu, L.; Hu, F.; Liu, J.; Deng, L. Tumor targeting and pH-responsive polyelectrolyte complex nanoparticles based on hyaluronic acid-paclitaxel conjugates and chitosan for oral delivery of paclitaxel. Macromol. Res. 2013, 21, 1331–1337.
85. Kumar, A.; Ahuja, M. Carboxymethyl gum kondagogu-chitosan polyelectrolyte complex nanoparticles: Preparation and characterization. Int. J. Biol. Macromol. 2013, 62, 80–84.
86. Arora, S.; Gupta, S.; Narang, R.K.; Budhiraja, R.D. Amoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for H. Pylori. Sci. Pharm. 2011, 79, 673–694.
87. Paliwal, R.; Paliwal, S.R.; Agrawal, G.P.; Vyas, S.P. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation. Int. J. Pharm. 2012, 422, 179–184.
88. Li, C.; Newman, R.A.; Wu, Q.P.; Ke, S.; Chen, W.; Hutto, T.; Kan, Z.; Brannan, M.D.; Charnsangavej, C.; Wallace, S. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemoth. Pharm. 2000, 46, 416–422.
89. Jain, A.K.; Swarnakar, N.K.; Godugu, C.; Singh, R.P.; Jain, S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials 2011, 32, 503–515.
90. Shelly; Ahuja, M.; Kumar, A. Gum ghatti-chitosan polyelectrolyte nanoparticles: Preparation and characterization. Int. J. Biol. Macromol. 2013, 61, 411–415.
91. Guo, R.; Chen, L.L.; Cai, S.S.; Liu, Z.H.; Zhu, Y.; Xue, W.; Zhang, Y.M. Novel alginate coated hydrophobically modified chitosan polyelectrolyte complex for the delivery of BSA. J. Mater. Sci.-Mater. Med. 2013, 24, 2093–2100.
92. Anitha, A.; Sreeranganathan, M.; Chennazhi, K.P.; Lakshmanan, V.; Jayakumar, R. In vitro combinatorial anticancer effects of 5-fluorouracil and curcumin loaded N,O-carboxymethyl chitosan nanoparticles toward colon cancer and in vivo pharmacokinetic studies. Eur. J. Pharm. Biopharm. 2014, 88, 238–251.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).